16 December 2025
Disclaimer: This is a simplified summary of a public company filing. See full disclaimer here.
Medtronic plc
CIK: 1613103•2 Annual Reports•Latest: 2025-06-20
10-K / June 20, 2025
Revenue:$33,537,000,000
Income:$4,662,000,000
10-K / June 20, 2024
Revenue:$32,364,000,000
Income:$3,705,000,000
10-K / June 20, 2025
Medtronic plc - Company Overview
Business Description
- Type: Global healthcare technology company
- Founded: 1949
- Headquarters: Galway, Ireland
- Presence: Serves healthcare systems, physicians, clinicians, and patients in more than 150 countries
Mission
- Core Mission: "To contribute to human welfare by applying biomedical engineering in research, design, manufacture, and sale of products to alleviate pain, restore health, and extend life."
- Strategic Focus:
- Accelerate innovation-driven growth with attractive markets and robust pipeline
- Deliver superior health outcomes and better experiences for patients and providers
- Leverage data, artificial intelligence (AI), and automation for real-time therapies and care
Workforce and Market
- Number of Employees: Over 95,000 full-time employees
- 44% based in the U.S. or Puerto Rico
- Revenue (Market Valuation):
- Market value of voting and non-voting common equity held by non-affiliates: Approximately $116.2 billion (as of October 25, 2024)
- Outstanding Shares: Approximately 1.28 billion (as of June 17, 2025)
Business Segments and Operations
- Segment Types:
- Cardiovascular Portfolio
- Neuroscience Portfolio
- Medical Surgical Portfolio
- Diabetes Operating Unit
- Products and Services:
- Device-based therapies primarily for cardiovascular, neurological, surgical, and diabetes care
- Software, digital solutions, and AI integration to improve treatment and healthcare delivery
Key Focus Areas
- Innovation & Growth:
- Launching new products, expanding pipeline, integrating AI and data analytics
- Patient and Provider Outcomes:
- Creating simpler, effective therapies with deep insights
- Global Expansion:
- Increasing adoption globally, especially in international markets
- Technology Integration:
- Incorporating AI, remote monitoring, and real-time therapy customization
Financial Highlights (Fiscal Year Ended April 25, 2025)
- Net Sales: Approximately $33.54 billion
- Operating Income (Net Income):
- $4.66 billion (GAAP)
- $7.08 billion (non-GAAP, excluding certain charges)
- Diluted Earnings Per Share (EPS):
- $3.61 (GAAP)
- $5.49 (non-GAAP)
- Revenue Growth: 4% increase from previous year
- Market Valuation: ~$116.2 billion (non-affiliates' market value)
- Employees: Over 95,000 full-time
Key Initiatives
- Focus on developing innovative therapies (e.g., minimally invasive surgical tools, advanced cardiac devices, neurostimulation systems, diabetes management tech)
- Separation planned for the Diabetes business (expected completion within 18 months of May 2025 announcement)
- Share repurchase programs, with approximately 38 million shares bought back in FY2025
This summary provides a detailed overview of Medtronic's core business operations, scale, financials, strategic focus, and product segments based solely on the provided document.
